19:12 , Dec 15, 2016 |  BC Innovations  |  Product R&D

p53 and Ras: Back from the dead

After decades of research and countless failed attempts at drug development, industry is reviving its interest in two of oncology’s most intractable targets, p53 and Ras. While no one denies there’s still a long road...